Article Type: Original Article

Subject category: Epidemiology

Risk prediction of atrial fibrillation based on electrocardiographic inter-atrial block

Running title: Skov et al.; Inter-atrial block and atrial fibrillation

Morten W. Skov, MD; Jonas Ghouse, MD; Jørgen T. Kühl, MD; Pyotr G. Platonov, MD, PhD; Claus Graff, MSc, PhD;
Andreas Fuchs, MD, PhD; Peter V. Rasmussen, MD; Adrian Pietersen, MD; Børge G. Nordestgaard, MD, DMSci;
Christian Torp-Pedersen, MD, DMSci; Steen M. Hansen, MD; Morten S. Olesen, MSc, PhD; Stig Haunsø, MD,
DMSci; Lars Køber, MD, DMSci; Thomas A. Gerds, PhD; Klaus F. Kofoed, MD, DMSci; Jesper H. Svendsen, MD,
DMSci; Anders G. Holst, MD, PhD; Jonas B. Nielsen, MD, PhD

Laboratory for Molecular Cardiology, The Heart Center, Rigshospitalet, University of Copenhagen, Copenhagen,
Denmark (M.W.S., J.G., P.V.R., M.S.O., S.H., J.H.S., A.G.H., J.B.N.); Department of Cardiology, The Heart Center,
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark (M.W.S., J.G., J.T.K., A.F., S.H., L.K., K.F.K.,
J.H.S.); Center for Integrative Electrocardiography at Lund University and Arrhythmia Clinic, Skåne University
Hospital, Lund, Sweden (P.G.P.); Department of Health Science and Technology, Aalborg University, Aalborg,
Denmark (C.G., C.T-P., S.M.H.); Copenhagen General Practitioners' Laboratory, Copenhagen, Denmark (A.P.);
Department of Clinical Biochemistry and the Copenhagen General Population Study, Herlev and Gentofte Hospital,
University of Copenhagen, Denmark (B.G.N.); Department of Clinical Medicine, Faculty of Health and Medical
Sciences, University of Copenhagen, Copenhagen, Denmark (B.G.N., S.H., L.K., J.H.S.); Department of
Biostatistics, University of Copenhagen, Copenhagen, Denmark (T.A.G.); Department of Radiology, Rigshospitalet,
University of Copenhagen, Denmark (K.F.K.); and Department of Internal Medicine, Division of Cardiovascular
Medicine, University of Michigan, Ann Arbor, MI, USA (J.B.N.).

Correspondence:

Jonas Bille Nielsen, MD, PhD Division of Cardiovascular Medicine Dept. of Internal Medicine University of Michigan 5804 Medical Science II 1241 E. Catherine St., Ann Arbor, MI 48109-5618 E-mail: jonas.bille.nielsen@gmail.com/Phone: (+1) (734) 647-6018.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the <u>Version of Record</u>. Please cite this article as <u>doi:</u> 10.xxxx/JAH3.3160

This article is protected by copyright. All rights reserved

Journal Subject Terms: Atrial Fibrillation; Computerized Tomography (CT); Electrocardiology (ECG); Epidemiology; Ischemic Stroke

Ianus \geq ut

Abstract

Background: The electrocardiographic inter-atrial block (IAB) has been associated with atrial fibrillation (AF). We aimed to test whether IAB can improve risk prediction of AF for the individual person.

Methods and Results: Digital electrocardiograms of 152,759 primary care patients aged 50-90 years were collected from 2001 to 2011. We identified individuals with P-wave \geq 120ms and the presence of none, one, two, or three biphasic P-waves in inferior leads. Data on comorbidity, medication, and outcomes were obtained from nationwide registries. We observed a dose-response relationship between the number of biphasic P-waves in inferior leads and the hazard of AF during follow-up. Discrimination of the 10-year outcome of AF, measured by time-dependent area under the curve, was increased by 1.09% (95% confidence interval [CI] 0.43%-1.74%) for individuals with cardiovascular disease at baseline (CVD) and 1.01% (95% CI 0.40%-1.62%) for individuals without CVD, when IAB was added to a conventional risk model for AF. The highest effect of IAB on the absolute risk of AF was observed in individuals aged 60-70 years with CVD. In this subgroup, the 10-year risk of AF was 50% in those with advanced IAB compared with 10% in those with a normal P-wave. In general, individuals with advanced IAB and no CVD had a higher risk of AF than patients with CVD and no IAB.

Conclusions: IAB improves risk prediction of AF when added to a conventional risk model. Clinicians may consider monitoring patients with IAB more closely for the occurrence of AF, especially for high-risk subgroups.

Key words: interatrial; risk prediction; atrial fibrillation; epidemiology; ECG; Inter-atrial block, Ischemic stroke

Clinical Perspective

What is New?

• Electrocardiographic inter-atrial block improves risk prediction of atrial fibrillation on an individual level; however, inter-atrial block does not seem to improve risk prediction of ischemic stroke.

• In general, individuals with advanced inter-atrial block and no cardiovascular disease had a higher risk of AF than patients with cardiovascular disease and no inter-atrial block.

What are the Clinical Implications?

- Clinicians may consider intensified monitoring of patients with inter-atrial block for the occurrence of AF, especially if the block is advanced with biphasic P-waves in all inferior ECG leads.
- We would argue against initiating anticoagulation treatment merely on the presence of IAB, as suggested by others.

Author Manus

The electrocardiographic inter-atrial block (IAB) typically exists when a conduction delay over the Bachmann's bundle is present, however, it can also be caused by intra-atrial conduction delay and left atrial enlargement. By analogy to other types of block, there is a continuum of IAB severity; partial IAB is defined as a P-wave duration \geq 120ms and advanced IAB is defined as P-wave duration \geq 120ms in conjunction with biphasic P-wave morphology in inferior leads II, III, and aVF.¹

There has been an increasing interest in IAB in recent years, especially regarding its role in atrial fibrillation (AF) and ischemic stroke.² In previous prospective studies of the general population (N~15,000), advanced IAB (yes/no) has been associated with an increased risk of AF and ischemic stroke.^{3,4} The observed increased risk of ischemic stroke was reported to be independent of AF as an intermediate step.⁴ For this reason, questions have been raised whether treatment with anticoagulation therapy in patients with IAB could be beneficial, regardless of AF status.^{4,5} However, to properly assess the clinical utility of a parameter with regards to risk stratification, knowledge on the absolute risks of AF and ischemic stroke associated with IAB is needed. Moreover, whether IAB is of clinical value in long-term risks of AF and ischemic stroke on an individual level has not been investigated.

Using a large middle-aged and elderly population of primary care patients, we aimed to i) replicate earlier findings of an association between IAB and an increased risk of AF and ischemic stroke, ii) examine differences in hazards according to the number of biphasic P-waves in inferior leads iii) investigate whether IAB is associated with conduction disorder and death from all causes, iv) evaluate whether IAB is of value in personalized long-term risk prediction of AF and ischemic stroke, v) to estimate absolute risks of AF and ischemic stroke based on IAB across clinically relevant subgroups, and finally, vi) to describe the association between IAB and left atrial end-diastolic volume.

Methods

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

Study population

This study is part of the Copenhagen electrocardiogram (ECG) study encompassing all persons who had an ECG recorded at the Copenhagen General Practitioners' Laboratory (CGPL) in the period 2001-2011, as described in details previously.⁶ For the present analyses, we excluded individuals

with the following characteristics at baseline: <50 or ≥90 years of age, AF, ischemic stroke, treatment with class I or III anti-arrhythmic drugs, treatment with warfarin or NOACs, and pacemaker or implantable cardioverter-defibrillator. Additionally, we excluded individuals with ECG findings inconsistent with interpretation of the IAB as noted in the Electrocardiography section.

According to Danish law, no approval from an ethics committee is needed in a registry-based study without any active participation from study subjects. The use of deidentified registry data was approved by the Danish Data Protection Agency.

Electrocardiography

All ECGs recorded at CGPL were digitally stored in the MUSE[®] Cardiology Information System, and processed using version 21 of the Marquette 12SL algorithm (GE Healthcare, Wauwatosa, Wisconsin, USA).⁶ The Marquette 12SL algorithm is a ECG analysis program.⁷ Using the 12SL algorithm, we excluded ECGs with rhythms different from sinus rhythm, multiple premature atrial or ventricular complexes, second and third degree atrioventricular blocks, heart rates below 30 or above 120 beats per minute, pace spikes, and ventricular preexcitation.⁶ We divided the population into 5 categories based on IAB; normal P-wave duration (<120 ms), partial IAB (P-wave duration ≥120ms and no biphasic [plus/minus] P waves in inferior leads) and three groups of IAB (P-wave duration \geq 120ms) associated with biphasic [plus/minus] P-waves in one, two, or three inferior leads (II, III, and aVF), the latter representing the strictly defined advanced IAB.^{1,2} P-wave duration was obtained as previously described,⁸ corresponding to the interval between the earliest detection of atrial depolarization in any lead and the latest detection of atrial depolarization in any lead. Amplitudes of significant waves within the P-wave are measured with respect to a baseline level that is interpolated from P onset to P offset. A wave crossing the baseline level which constitutes an area of $\geq 160 \,\mu$ V-ms is considered a separate and significant wave. The 12SL algorithm accommodates the phenomena of PR depression. As such, IAB was defined by ourselves based on the 12SL algorithm's measurements of lead-specific amplitudes and global P-wave duration. Examples of IAB according to number of biphasic P-waves in inferior leads are illustrated in Figure 1. In a supplemental analysis, we also divided the population into eight categories based on which inferior leads, or combination of leads, were affected by a biphasic P-wave. We found excellent agreement between the 12SL algorithm and manual interpretation in the detection of IAB. We did an enriched random sampling of 25 normal ECGs, 25 with partial IAB, 25 with IAB and

one biphasic P-wave in inferior leads, 25 with IAB and two biphasic P-waves in inferior leads, and 25 with advanced IAB and three biphasic P-waves in inferior leads all detected by 12SL. Extraction of ECGs for the purpose of manual validation was done by C.G., manual interpretation of the ECGs blinded to the 12SL interpretation was done by M.W.S., and comparison between 12SL detected IAB and manual detected IAB was done by J.B.N. We observed an unweighted and weighted kappa of 0.98 (0.95-0.98) and 1.0 (0.99-1.0), respectively.

Baseline variables and follow-up

All persons with permanent residence in Denmark are allocated a unique and personal identification number which enables linkage of data across multiple nationwide healthcare registries. This makes it possible to gather information on death, emigration, the use of prescription medication and any hospital, out-patient clinic, or emergency room discharge diagnosis on an individual level.⁹ Individuals with the following characteristics at baseline were identified: hypertension, valvular heart disease, ischemic heart disease (IHD), heart failure (HF), diabetes, hyperthyroidism, obesity, sleep apnea, and anti-platelet use. Hypertension was defined from discharge diagnosis or if a subject prior to inclusion was treated simultaneously with at least two types of antihypertensive drugs.¹⁰ Valvular heart disease was defined from discharge diagnosis, procedure, and operation codes.¹⁰ IHD was defined from discharge diagnoses of stabile angina pectoris or acute coronary syndrome. HF was defined as a discharge diagnosis of HF in combination with treatment with loop diuretics.¹⁰ Diabetes and hyperthyroidism were defined from discharge diagnosis or in case of a purchase of prescription medication used for one of the two diseases. Obesity was defined from discharge diagnosis.¹¹ Anti-platelet use was defined from dispensed prescriptions. AF was the outcome of primary interest and was defined from hospital, out-patient clinic, or emergency room discharge diagnoses.¹⁰ Secondary endpoints were ischemic stroke, death from all causes and a combined endpoint of sick sinus node syndrome and 3rd degree atrio-ventricular block, named 'conduction disorder' hereafter. Detailed information on the identification of covariates and clinical outcomes in the Danish registries is available in Table S1 and S2. Follow-up began on the day of the first ECG recording (index ECG) and ended in case of the event of interest, death, emigration, or at December 31, 2013, whichever occurred first.

Cardiac computed tomography scan population

To determine the relationship between left atrial size and IAB, we included data from a population with available contrast enhanced low-dose cardiac computed tomography (CT) scans and digital ECGs. These individuals, randomly sampled from the general population in Copenhagen, were participants in the Copenhagen General Population Study.¹²

All cardiac CT scans were obtained in late diastole just before atrial contraction. Left atrial volume was manually assessed, as described in details previously.¹³ A high degree of agreement with magnetic resonance imaging as well as a low inter-observer variability has been observed.¹³

Written informed consent was obtained from all participants, and the study was approved by the local ethics committee (H-KF-01-144/01).

Statistical analyses

Time-on-study was used as timescale in all survival analyses. The median follow-up time was estimated with the reverse Kaplan-Meier method.¹⁴

A two-sided P-value of <0.05 was considered statistically significant. All analyses were conducted with the use of Stata 14.0 software package (StataCorp LP, College Station, Texas, USA) and R [R Foundation for Statistical Computing, Vienna, Austria (URL <u>http://www.R-project.org/)]</u>.

Association analyses

Cause-specific Cox regression was used to assess the association of IAB on the index ECG with the hazard rate of AF, ischemic stroke, conduction disorder, and death, respectively, during follow-up. All Cox models were adjusted for age, sex, hypertension, valvular heart disease, IHD, HF, diabetes, hyperthyroidism, obesity, sleep apnea, anti-platelet use, heart rate (categorized into tertiles), and Sokolow-Lyon ECG criteria of left ventricular hypertrophy. The category with a P-wave duration <120ms (normal P-wave duration) was chosen as reference. In supplemental analyses individuals with one or two biphasic P-waves were further subdivided regarding which leads were affected. In this setting, the combination of two biphasic P-waves in leads II and III were excluded as only six individuals had this combination of two biphasic P-waves.

As a sensitivity analysis, the direct association between IAB and the risk of ischemic stroke, independent of AF as a possible intermediate step, was assessed by censoring individuals in case of incident AF.

Risk prediction

Risk prediction analyses were conducted for 10-year outcome separately for individuals with and without cardiovascular disease (CVD) at baseline. CVD was defined as present if any of the following was present at baseline; valvular heart disease, HF, IHD, or hypertension. The 10-year risks of AF and ischemic stroke were predicted in a competing risk setting by combining a Cox model for all-cause mortality and a Cox model for the outcome of interest.¹⁵ The time-dependent area under the receiving operating characteristics curve (AUC) was calculated in order to evaluate the added discriminative value of IAB for the purpose of AF- and ischemic stroke-specific risk prediction.¹⁶ AUC corresponds to the probability that a person who experiences the event of interest (AF or ischemic stroke) within 10 years receives a higher predicted risk than that of a person who does not (dies or is alive 10 years after ECG). To estimate the 10-year AUC, we split the data into a training set (63%) and test set (37%). Since the results of this approach may depend on how the data is split, we split the dataset 1001 times at random and then reported results for the split which corresponds to the median AUC in the 1001 models without IAB. Differences in AUC between models with and without IAB were calculated to assess the effect of adding IAB to conventional risk models for AF and ischemic stroke. Brier scores were calculated in order to evaluate model calibration.¹⁷ To illustrate the time-trends of the predicted risks of AF and ischemic stroke, we calculated the average risks within 10-year age-groups for all combinations of CVD/no CVD and IAB pattern. Predictions for cumulative incidence curves were based on multivariable-adjusted Cox models fitted within the respective 10-year age-group and CVD subgroup (yes/no). Age within the various 10-year age-groups was included as a covariate.

Relationship between IAB and left atrial volume in the CT study population

Two approaches were used to describe the relationship between IAB and left atrial end-diastolic volume in the CT study population. First, the direct association between IAB and left atrial end-diastolic volume were descriptively assessed by means of a violin plot (comparing medians, interquartile range [IQR], range). Secondly, to adjust for age and sex differences across IAB subgroups, we constructed two logistic regression models with IAB as outcome (yes/no): Model 1 included age and sex and model 2 included age, sex, and left atrial end-diastolic volume. AUC was calculated to compare the two models.

Results

A total of 343,607 individuals had an ECG recorded at CGPL during the 11-year study period, and of these 152,759 (45%) individuals were eligible for inclusion. Baseline characteristics of the study population are presented in **Table 1**. In general, the more advanced IAB, the higher burden of comorbidity. The median follow-up time was 9.2 years (IQR 6.3-11.3). During follow-up, 12,657 persons were diagnosed with incident AF, 13,497 were diagnosed with ischemic stroke, 2,040 developed a conduction disorder, and 34,196 died.

For lead specific distribution of one or two biphasic P-waves in inferior leads, please see **Table S3**. The most common inferior lead affected by a biphasic P-wave was lead III.

Association analyses in the whole population

In general, we observed a dose-response association between the number of biphasic P-waves in inferior leads and the hazard of the various outcomes investigated (**Figure 2**). The associations were particularly strong with respect to development of AF and other conduction disorders. For advanced IAB, the hazard ratio was 3.38 (95% confidence interval [CI] 2.99-3.81) for developing AF, 1.45 (95% CI 1.23-1.70) for developing ischemic stroke, 3.27 (95% CI 2.52-4.23) for developing conduction disorder, and 1.35 (95% CI 1.23-1-47) for all-cause mortality compared to the population without IAB. The association with the hazard rate of ischemic stroke was maintained when AF was considered a competing risk (**Table S4**). The association analyses considering which inferior leads that were affected by a biphasic P-wave, or combinations hereof, and the hazard rate of the various outcomes are presented in **Figure S1**. In general, the association with AF, ischemic stroke, and conduction disorder were particularly strong for combinations involving a biphasic P-wave in inferior lead II.

Risk prediction of atrial fibrillation and ischemic stroke

Figure 3 displays the differences in AUC for the 10-year outcomes of AF and ischemic stroke obtained by adding IAB to conventional risk models for AF and ischemic stroke, respectively. Adding IAB to a conventional risk model for AF significantly increased AUC for the 10-year risk of AF in both groups of individuals: with CVD (difference in AUC, 1.09%: 95% CI, 0.43%-1.74%) and without CVD at baseline (difference in AUC, 1.01%: 95% CI, 0.40%-1.62%). For ischemic stroke as outcome, no significant changes in AUC for the 10-year prediction of ischemic stroke in both individuals with and without CVD at baseline were observed when adding IAB to a

conventional risk model for ischemic stroke. Brier scores were significantly lower for models with IAB compared to conventional risk models for both AF and ischemic stroke as outcome.

Absolute risk of atrial fibrillation and ischemic stroke

The median absolute risks of AF and ischemic stroke within the respective age- and CVD-groups are provided in **Figure 4** and **Figure 5**, respectively. The highest absolute risk of AF was observed for individuals with advanced IAB (three biphasic P-waves) and CVD in the age-group 60-70 years. A total of 50% of the individuals in this subgroup developed AF within 10 years of follow-up compared with 10% in those with normal P-wave. The importance of IAB for individual risk predictions of AF within 1, 5, and 10 years from ECG according to different risk profiles is illustrated in **Table S5**.

Regarding stroke as outcome, the highest absolute risks were observed in those with advanced IAB (three biphasic P-waves) and CVD aged 60-70 years and in those with no CVD aged 80-90 years, respectively. In these subgroups, the absolute risks of developing ischemic stroke during 10 years of follow-up were 20% and 25%, respectively, compared with 11% and 16% in those with normal P-wave, respectively.

For median absolute risk of conduction disorder within the respective age- and CVD subgroups, see **Figure S2**.

Relationship between IAB and left atrial volume in the CT study population

A total of 5,051 individuals had a cardiac CT and ECG obtained in sinus rhythm. The median age was 59 years (IQR 51-67 years) and 54% were women. **Figure 6A** displays the relationship between varying degrees of IAB and left atrial end-diastolic volume without taking age and sex into account. The more advanced IAB, the greater the left atrial end-diastolic volume. **Figure 6B** shows the receiving operator curve for two models predicting IAB (yes/no). The AUC was 65% in the model containing age and sex only, whereas the AUC was 70% for the model including left atrial end-diastolic volume, besides age and sex.

Discussion

In this large ECG population, we i) confirmed previous findings of an association between IAB and AF and ischemic stroke, ii) present novel findings of an association between IAB and conduction disorder, iii) found that adding IAB to a conventional risk model for AF might improve the

accuracy of personalized AF prognosis, iv) found clinically relevant differences in long-term absolute risks of AF and ischemic stroke associated with IAB in several subgroups, and v) found that adding IAB to a conventional risk model for ischemic stroke did not improve risk prediction of ischemic stroke on an individual level.

In line with our results, previous prospective studies of the general population (N~15,000) have also reported an association between advanced IAB (yes/no) and an increased risk of AF and ischemic stroke.^{3,4} However; due to a population of >150,000 individuals, we were able to nuance these findings by looking at IAB with one, two, or three biphasic P-waves in inferior leads. Interestingly, we found a dose-response association between severity of IAB and the risk of AF and ischemic stroke. As evident from **Figure S1**, the association with AF, ischemic stroke, and conduction disorder were particularly strong for combinations involving a biphasic P-wave in lead II, either isolated or in combination with a biphasic P-wave in lead aVF. As such, there seems to be a gradient of pathogenicity, with a biphasic P-wave in lead III or its combination with a biphasic P-wave in lead aVF (two biphasic P-waves) being the most prevalent and associated with better prognosis compared to biphasic P-waves involving lead II.

To test whether IAB could improve risk prediction of AF and ischemic stroke on an individual level, we calculated measures of discrimination. This is important to examine because an association between a given parameter and outcome does not necessarily translate into something meaningful for the individual patient.¹⁸ When IAB was added to a model containing several well-established risk factors for AF, it significantly improved AUC by ~1%-point for both individuals with and without CVD at baseline. We believe that such an impact on AUC, although modest, may have clinical implications. In contrast, a recent study found no improvement in *C*-statistics for PR interval, P wave duration, P area, or P terminal force, respectively, when added to a conventional risk model for AF.¹⁹ For ischemic stroke as outcome, no improvement in AUC was observed. As such, IAB does not seem to add anything in risk prediction of ischemic stroke on an individual level. For this reason, we would argue against initiating anticoagulation treatment merely on the presence of IAB, as speculated previously.^{4,5}

From a clinical perspective, absolute risks are preferable in comparison to relative risks. As such, we estimated long-term absolute risks of AF and ischemic stroke in different subgroups based on IAB. We have presented these results as cumulative risk taking into account the competing risk of death. This implies that we are presenting the probability of being alive and developing a condition. When the absolute risk increased most for people with intermediate age

compared to the very old this reflects a higher risk of the competing risk of death in the very old. A total of 50% of the individuals aged 60-70 with cardiovascular disease and advanced IAB (three biphasic P-waves) developed AF within 10 years of follow-up compared to 10% in those with normal P-wave. Accordingly, the 60-70-year-old individual with cardiovascular disease and advanced IAB seems to be at an increased risk of AF that should not be ignored in clinical practice. Interestingly, patients with IAB and no cardiovascular disease had a higher risk of AF than patients with hypertension, valvular heart disease, heart failure, and/or ischemic heart disease and no IAB. These data suggest that clinicians may consider monitoring patients with IAB closely for the occurrence of AF, especially for high-risk subgroups. This could be in the form of modern technology, such as different smartphone dependent devices or other wearables.²⁰

We found that IAB on average is associated with larger left atrial end-diastolic volume. However; part of this association was driven by higher age in those with advanced IAB compared to those without IAB. Moreover, it is well documented that IAB can exist without evidence of left atrial enlargement.¹ As such, the electrocardiographic IAB is probably a composite of impaired atrial conduction velocity and left atrial enlargement, both contributing to the observed increased risk of AF.^{1,21}



Since our study population only included individuals aged 50–90 years, we cannot extrapolate the current findings to other age-groups. The reason for excluding individuals younger than 50 years old was due to statistical power – very few individuals younger than 50 years have advanced IAB and events of interests.

The study relied on Danish administrative registries regarding data on medication use, morbidity and mortality and for some of the entries we do not know the validity. However, a registry-based diagnosis of AF has been found to have a positive predictive value of 93% for electrocardiographically documented AF.²² High positive predictive values have also been found for our register-based definition of heart failure, ischemic stroke, and hypertension.¹⁰

Conclusions

In a large primary care population, we found that IAB is associated with increased hazards of AF, ischemic stroke, conduction disorder, and death from all causes. IAB improved risk prediction of

AF on an individual level when added to a conventional risk model. For many clinically relevant subgroups, the risk of AF among those with IAB was increased to an extent that could guide clinical decision making. For ischemic stroke as outcome, IAB does not seem to add anything in risk prediction on an individual level.

Funding Sources: This work was supported by The Research Foundation at Copenhagen University Hospital, Rigshospitalet; Fonden til Lægevidenskabens Fremme (The A.P. Møller and Chastine Mc-Kinney Møller Foundation for General Purposes); the John and Birthe Meyer Foundation; and Fondsbørsvekselerer Henry Hansen og Hustru Karla Hansen Født Vestergaards Legat.

Disclosures: A.G.H. is an employee of Novo Nordisk A/S, Denmark. J.H.S. has received research grants from Medtronic, Biotronik and Gilead, personal fees as speaker for Medtronic, Biotronik and Boehringer Ingelheim and personal fees as a member of an advisory committee in Medtronic. L.K. has received speaker honorarium from Servier and Novartis. C.T.P. has received research grants and speaker honoraria from Bayer and research grants from Biotronik. S.M.H. has received research grants from The Danish Foundation Trygfonden, The Danish Heart Foundation, and The Laerdal Foundation. The remaining authors have no disclosures to report.

References:

1. Bayés de Luna A, Platonov P, Cosio FG, Cygankiewicz I, Pastore C, Baranowski R, Bayés-Genis A, Guindo J, Viñolas X, Garcia-Niebla J, Barbosa R, Stern S, Spodick D. Interatrial blocks. A separate entity from left atrial enlargement: a consensus report. *J Electrocardiol*. 2012;45:445–451.

2. Martínez-Sellés M, Baranchuk A, Elosua R, de Luna AB. Rationale and design of the BAYES (Interatrial Block and Yearly Events) registry. *Clin Cardiol*. 2017;40:196–199.

3. O'Neal WT, Zhang Z-M, Loehr LR, Chen LY, Alonso A, Soliman EZ. Electrocardiographic Advanced Interatrial Block and Atrial Fibrillation Risk in the General Population. *Am J Cardiol*. 2016;117:1755–1759.

4. O'Neal WT, Kamel H, Zhang Z-M, Chen LY, Alonso A, Soliman EZ. Advanced interatrial block and ischemic stroke: The Atherosclerosis Risk in Communities Study. *Neurology*. 2016;87:352–356.

5. Martínez-Sellés M, García-Izquierdo Jaén E, Fernández Lozano I. Anticoagulation in elderly patients at high risk of atrial fibrillation without documented arrhythmias. *J Geriatr Cardiol*. 2017;14:166–168.

Nielsen JB, Graff C, Pietersen A, Lind B, Struijk JJ, Olesen MS, Haunsø S, Gerds TA, Svendsen JH, Køber L, Holst AG. J-shaped association between QTc interval duration and the risk of atrial fibrillation: results from the Copenhagen ECG study. *J Am Coll Cardiol*. 2013;61:2557–2564.

MarquetteTM 12SLTM ECG Analysis Program Physician's Guide 2036070-006
 Revision C, 2010, 2012 General Electric Company.

8. Nielsen JB, Kühl JT, Pietersen A, Graff C, Lind B, Struijk JJ, Olesen MS, Sinner MF, Bachmann TN, Haunsø S, Nordestgaard BG, Ellinor PT, Svendsen JH, Kofoed KF, Køber L, Holst AG. P-wave duration and the risk of atrial fibrillation: Results from the Copenhagen ECG Study. *Heart Rhythm.* 2015;12:1887–1895.

9. Frank L. Epidemiology. When an entire country is a cohort. *Science*. 2000;287:2398–2399.

10. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen A-MS, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. *BMJ*. 2011;342:d124.

11. Christiansen MN, Køber L, Weeke P, Vasan RS, Jeppesen JL, Smith JG, Gislason GH, Torp-Pedersen C, Andersson C. Age-Specific Trends in Incidence, Mortality, and Comorbidities of Heart Failure in Denmark, 1995 to 2012. *Circulation*. 2017;135:1214–1223.

12. Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjærg-Hansen A, Smith GD, Timpson NJ. The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach. *PLOS Med.* 2012;9:e1001212.

13. Kühl JT, Lønborg J, Fuchs A, Andersen MJ, Vejlstrup N, Kelbæk H, Engstrøm T, Møller JE, Kofoed KF. Assessment of left atrial volume and function: a comparative study between echocardiography, magnetic resonance imaging and multi slice computed tomography. *Int J Cardiovasc Imaging*. 2012;28:1061–1071.

14. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials*. 1996;17:343–346.

Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies.
 Biometrics. 1990;46:813–826.

16. Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing timedependent areas under receiver operating characteristic curves for censored event times with competing risks. *Stat Med.* 2013;32:5381–5397.

17. Gerds TA, Scheike TH, Andersen PK. Absolute risk regression for competing risks: interpretation, link functions, and prediction. *Stat Med.* 2012;31:3921–3930.

18. Wolbers M, Blanche P, Koller MT, Witteman JCM, Gerds TA. Concordance for prognostic models with competing risks. *Biostat Oxf Engl.* 2014;15:526–539.

Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, Benjamin EJ,
Alonso A. P-wave indices and atrial fibrillation: cross-cohort assessments from the Framingham
Heart Study (FHS) and Atherosclerosis Risk in Communities (ARIC) study. *Am Heart J*.
2015;169:53–61.e1.

20. Olgun Kucuk H, Kucuk U, Yalcin M, Isilak Z. Time to use mobile health devices to diagnose paroxysmal atrial fibrillation. *Int J Cardiol*. 2016;222:1061.

21. Goyal SB, Spodick DH. Electromechanical dysfunction of the left atrium associated with interatrial block. *Am Heart J*. 2001;142:823–827.

22. Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry. *Scand Cardiovasc J.* 2012;46:149–153.

Autho

			Inter-atrial block		
	No IAB	Partial IAB	IAB,	IAB,	Advanced IAB,
	NUIAD	I al ual IAD	One biphasic P-wave	Two biphasic P-waves	Three biphasic P-waves
Total count – n (%)	113,204 (74)	24,403 (16)	11,888 (7.8)	2,442 (1.6)	822 (0.5)
Age (years) – median (IQR)	63 (56 – 72)	65 (58 - 74)	66 (59 - 75)	72 (64 - 80)	78 (71 – 84)
Women – n (%)	69,199 (61)	12,045 (49)	4,838 (41)	999 (41)	379 (46)
Medical history – n (%)					
Hypertension	25,995 (23)	7,350 (30)	4,386 (37)	1,035 (42)	377 (46)
Valvular heart disease	359 (0.3)	111 (0.5)	62 (0.5)	23 (0.9)	9 (1.1)
Heart failure	952 (0.8)	302 (1.2)	178 (1.5)	53 (2.2)	38 (4.6)
Ischemic heart disease	7,869 (7.0)	2,051 (8.4)	1,272 (10.7)	296 (12.1)	102 (12.4)
Diabetes Mellitus	7,306 (6.5)	1,669 (6.8)	979 (8.2)	265 (10.9)	121 (14.7)
Hyperthyroidism	1,770 (1.6)	420 (1.7)	179 (1.5)	40 (1.6)	14 (1.7)
Anti-platelets	17,655 (16)	4,537 (19)	2,679 (23)	664 (27)	270 (33)
Obesity	1,713 (1.5)	447 (1.8)	296 (2.5)	57 (2.3)	31 (3.8)
Sleep apnea	500 (0.4)	132 (0.5)	103 (0.9)	17 (0.7)	4 (0.5)
CHA ₂ DS ₂ VASc					
0 points	51,428 (45.4)	8,846 (36.2)	3,675 (30.9)	445 (18.2)	55 (6.7)
1 point	11,650 (10.3)	3,528 (14.5)	2,087 (17.6)	406 (16.6)	87 (10.6)
≥ 2 points	50,126 (44.3)	12,029 (49.3)	6,126 (51.5)	1,591 (65.2)	680 (82.7)
ECG variables					
Heart rate (beats/min) – median (IQR)	71 (63 – 80)	71 (63 – 83)	68 (61 – 77)	68 (61 – 76)	70 (62 - 80)
Left ventricular hypertrophy – n (%)	3,910 (3.4)	1,415 (5.7)	606 (5.0)	178 (7.1)	59 (7.0)

This article is protected by copyright. All rights reserved

For all baseline variables, except hyperthyroidism (P=0.56), we found that the observed differences in medians and proportions were statistically significant (P<0.001) different across the 5 IAB-defined subgroups when calculating P for trend. Ischemic stroke is not included in CHA_2DS_2 VASc since individuals with ischemic stroke were excluded at baseline. IAB; Inter-atrial block, IQR; Interquartile range

_ Manusc Author

Figure Legends:

Figure 1. Examples of inter-atrial block as well as a normal electrocardiogram. IAB=Inter-atrial block.

Figure 2. Multivariable-adjusted hazard ratios for atrial fibrillation, ischemic stroke, conduction disorder, and all-cause mortality by inter-atrial block. IAB=Inter-atrial block; CI₉₅=95% confidence interval.


Figure 3. Differences in area under the curve for the 10-year outcomes of atrial fibrillation and ischemic stroke obtained by adding inter-atrial block to conventional risk models for atrial fibrillation and ischemic stroke, respectively, stratified by the presence or absence of cardiovascular disease at baseline. AF=atrial fibrillation; AUC=area under the curve; CI=confidence interval; CVD=cardiovascular disease at baseline; IAB=inter-atrial block; noCVD=no cardiovascular disease at baseline.

Figure 4. Cumulative incidence curves of inter-atrial block for the outcome of atrial fibrillation in patients with and without cardiovascular disease at baseline and stratified into 10-year age-groups. Predictions were based on multivariable-adjusted Cox models fitted within the respective age-group and cardiovascular disease group (yes/no). AF=atrial fibrillation; CVD=cardiovascular disease; ECG=electrocardiogram; IAB=inter-atrial block.

Figure 5. Cumulative incidence curves of inter-atrial block for the outcome of ischemic stroke in patients with and without cardiovascular disease at baseline and stratified into 10-year age-groups. Predictions were based on multivariable-adjusted Cox models fitted within the respective age-group and cardiovascular disease group (yes/no). CVD=cardiovascular disease; ECG=electrocardiogram; IAB=inter-atrial block.

Figure 6. A) Violin plot displaying median, interquartile range, range, and probability density of left atrial enddiastolic volume for normal P-wave and inter-atrial block. IAB-1=inter-atrial block with one biphasic P-wave in inferior leads; IAB-2=inter-atrial block with two biphasic P-waves in inferior leads; IAB=inter-atrial block. B) Receiving operator curve for the two models. In both models, inter-atrial block (yes/no) is outcome. AUC=area under the curve; LAEDV=left atrial end-diastolic volume.

Auth



Outcome	Interatrial block (IAB)		Cl ₀₅
Atrial Fibrillation	No IAB		Reference
	Padial IAB	2.00	1.25 (1.19-1.30)
	IAB, one biphasic		1.48 (1.40-1.56)
+	IAB, two biphasic	•	2.07 (1.89-2.27)
	Advanced IAB, three biphasic	-	3.38 (2.99-3.81)
Ischemicistroke	No IAB	•	Reference
	Partial IAB	•	1.00 (0.96-1.05)
\mathbf{O}	IAB, one biphasic	•	1.09 (1.02-1.15)
()	IAB, two biphasic		1.25 (1.12-1.39)
	Advanced IAB, three biphasic	•	1.45 (1.23-1.70)
Conduction divorder	No IAB	•	Reference
	Partial IAB	•	1.09 (0.97-1.23)
	IAB, one biphasic	•	1.43 (1.25-1.64)
\mathbf{U}	IAB, two biphasic		2.07 (1.69-2.55)
	Advanced IAB, three biphasic		3.27 (2.52-4.23)
All-cause mortality	No IAB	•	Reference
	Partial IAB	•	0.99 (0.97-1.02)
	IAB, one biphasic	•	0.96 (0.92-0.99)
	IAB, two biphasic	•	1.09 (1.02-1.16)
	Advanced IAB, three biphasic	•	1.35 (1.23-1.47)
		0 1 2 3 4 5 Hazard Ratio	
	jah3_3160		

This article is protected by copyright. All rights reserved

Outcome Population Model

AUC	195%
Ph L 1 2	100.00

Outcome	Populatio	n Model		AUC	[95% CI]	P-valu
ĄF	NoCVD	Conventional model		66.00%	[60.90% to 71.10%]	
		IAB model vs. conventional model		1.01%	[0.40% to 1.62%]	0.001
	CVD	Conventional model	•	63.80%	[61.00% to 86.60%]	
	_	IAB model vs. conventional model		1.09%	[0.43% to 1.74%]	0.001
Stroke	Notivo	Conventional model		64.90%	[59.60% to 70.20%]	
		AB model vs. conventional model	-	0.08%	[-0.11% to 0.28%]	0.415
	CVD	Conventional model		60.60%	(58.00% to 63.30%)	
		IAB model vs. conventional model		0.03%	[-0,45% to 0.50%]	0.908
	C	5	-2 -1 0 1 2 Difference in AUC (%)			
		jah	3_3160_f3.tiff			
	Nanic	5				

